MARKET

GNCA

GNCA

Genocea Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.0651
-0.0090
-12.15%
Opening 10:46 05/27 EDT
OPEN
0.0736
PREV CLOSE
0.0741
HIGH
0.0736
LOW
0.0621
VOLUME
10.72M
TURNOVER
344.48K
52 WEEK HIGH
2.680
52 WEEK LOW
0.0590
MARKET CAP
3.83M
P/E (TTM)
-0.1231
1D
5D
1M
3M
1Y
5Y
20 Stocks Moving in Thursday's Pre-Market Session
Gainers TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares rose 51.2% to $0.9603 in pre-market trading after dipping 18% on Wednesday.
Benzinga · 1d ago
GRPN, GNCA and LAB among mid-day movers
=Gainers: BlackSky Technology (BKSY) +93%. StoneMor (STON) +51%. Genocea Biosciences (GNCA) +35%. Hoegh LNG Partners (HMLP) +31%. Caleres (CAL) +27%. Evelo Biosciences (EVLO) +20%. Spire Global (SPIR) +17%. Groupon (GRPN)
Seekingalpha · 1d ago
HAPP Stock Soars 38% as Happiness Development Embraces EVs
Investor Place · 2d ago
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.
Investor Place · 2d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Investor Place · 2d ago
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading.
Benzinga · 2d ago
Three weeks after layoffs, Genocea shuts down entirely
The Cambridge company made the decision just three weeks after announcing it was laying off 65% of its staff and exploring a sale.
American City Business Journals · 2d ago
More
No Data
Learn about the latest financial forecast of GNCA. Analyze the recent business situations of Genocea Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
33.33%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GNCA stock price target is 3.080 with a high estimate of 6.00 and a low estimate of 0.1600.
High6.00
Average3.080
Low0.1600
Current 0.0653
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 61
Institutional Holdings: 34.54M
% Owned: 58.75%
Shares Outstanding: 58.78M
TypeInstitutionsShares
Increased
7
62.30K
New
5
93.89K
Decreased
6
378.88K
Sold Out
4
71.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.28%
Pharmaceuticals & Medical Research
+0.42%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Director
William Clark
Chief Financial Officer
Diantha Duvall
Executive Vice President
Raymond Stapleton
Chief Scientific Officer
Jessica Flechtner
Other
Girish Aakalu
Other
Thomas Davis
Independent Director
Ali Behbahani
Independent Director
Katrine Bosley
Independent Director
Jennifer Herron
Independent Director
Michael Higgins
Independent Director
John Lunger
Independent Director
George Siber
No Data
No Data
About GNCA
Genocea Biosciences, Inc. is a biopharmaceutical company that is engaged in discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) technology platform. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Its programs include GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. Its GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral T cells (NPTs). The GEN-011 NPTs is preferred for ATLAS-identified anti-tumor antigens that are used to manufacture a peripheral blood-derived, tumor-specific T cell therapy.

Webull offers kinds of Genocea Biosciences Inc stock information, including NASDAQ:GNCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNCA stock methods without spending real money on the virtual paper trading platform.